Drug shows promise in keeping aggressive leukemia at bay after transplant
Disease control
Completed
This study looked at whether the drug gilteritinib helps keep acute myeloid leukemia (AML) from returning after a stem cell transplant in patients with a specific genetic change (FLT3). Researchers compared two groups: one from previous trials who received gilteritinib after tran…
Sponsor: Astellas Pharma Singapore Pte. Ltd. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC